$CALA News
Last published 3y ago
- 3y agoCALACalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic
- 4y agoCALACalithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022
- 4y agoCALACalithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Tr
- 4y agoCALACalithera to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and
- 4y agoCALAGlutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer - NCT05521997ClinicalTrials.govProgression-free survival (PFS) - experimental arm only, Acute toxicity as measured by number of acute adverse events experienced by participant - experimental arm only, Late toxicity as measured by number of late adverse events experienced by participant - experimental arm only, (and 4 more...)
- 4y agoCALACalithera Biosciences Reports Second Quarter 2022 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
- 4y agoCALACalithera Biosciences (CALA) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsCALA earnings call for the period ending June 30, 2022.
- 4y agoCALACalithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's second quarter 2022 financial results will be released o
- 4y agoCALACalithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma ConferencesGlobeNewswire-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib
- 4y agoCALACalithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung CancerGlobeNewswire-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-onc
- 4y agoCALACalithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell LymphomaGlobeNewswire-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or CD79b mutation
- 4y agoCALACalithera Biosciences Announces 1-for-20 Reverse Stock SplitGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has filed a Certificate of Amendment to its Amended and R
- 4y agoCALACalithera to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and c
- 4y agoCALACalithera Biosciences (CALA) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsCALA earnings call for the period ending March 31, 2022.
- 4y agoCALACalithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's first quarter 2022 financial results will be rel
- 4y agoATERCALAMNDTT+1Thinking about buying stock in AT&T, Calithera Biosciences, Aterian, Mandiant, or Xerox?PR NewswireNEW YORK, April 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for T, CALA, ATER, MNDT, and XRX. To
- 4y agoCALACalithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal CompoundsGlobeNewswireFindings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers VPS4A and VPS4B are gene paralogs that show strong synthetic lethal interactio
- 4y agoCALAStudy of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - NCT05319028ClinicalTrials.govOverall Response Rate (ORR) as assessed by an independent radiology review committee (IRC) according to the 2014 International Working Group (IWG) Lugano Criteria (Cheson, 2014)., Safety as measured by type, incidence, severity, seriousness, and study drug-relatedness of adverse events per Common Terminology Criteria for Adverse Events, version 5, Duration of Response (DOR) Rate as assessed by an ...
- 4y agoCALACalithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the fourth quarter and year ended Decem
- 4y agoCALACalithera Biosciences (CALA) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsCALA earnings call for the period ending December 31, 2021.
- 4y agoCALACalithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing of its previously announced underwritten public offer
- 4y agoCALACalithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, war
- 4y agoCALACalithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's fourth quarter and full year 2021 financial re
- 4y agoCALAA Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer - NCT05275673ClinicalTrials.govInvestigator-Assessed Overall Response Rate (ORR) per RECIST v1.1., Number of Participants With Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs, Duration of Response (DOR), (and 4 more...)
- 4y agoCALACalithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it will present the first data from its preclinical syntheti
- 4y agoCALACalithera to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and
- 4y agoBBIGCALADIDIPIXY+1Thinking about buying stock in SoFi Technologies, Vinco Ventures, DiDi Global, Calithera Biosciences, or ShiftPixy?PR NewswireNEW YORK, Jan. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, BBIG, DIDI, CALA, and PIXY.
- 4y agoCALAAN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease ProgramPR NewswireMENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several
- 4y agoCALACalithera to Present at the H.C. Wainwright BioConnect Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and
- 4y agoCALADRNAMRAAS+1Thinking about buying stock in Dicerna Pharmaceuticals, Cloopen Group, Calithera Biosciences, ZTO Express, or Macy's?PR NewswireNEW YORK, Nov. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRNA, RAAS, CALA, ZTO, and M. To s
- 5y agoCALACalithera to Present at the 2021 Jefferies London Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and
- 5y agoCALACalithera Biosciences Reports Third Quarter 2021 Financial Results and Recent HighlightsGlobeNewswire-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of Sep
- 5y agoCALACalithera Biosciences, Inc (CALA) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsCALA earnings call for the period ending September 30, 2021.
- 5y agoCALACalithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical TrialGlobeNewswire--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as well as the ongoing trial of CB-2
- 5y agoCALACalithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the promotion of current vice president and head of clinical devel
- 5y agoCALACalithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's third quarter 2021 financial results will be r
- 5y agoCALACalithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021GlobeNewswire-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride-- Early positive trend seen in FEV1, a safety endpoint
- 5y agoCALACalithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company's investigational arginase in
- 5y agoCALACalithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda PharmaceuticalsGlobeNewswire-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company's precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022 -- -- Calithera to host webcast and conf
- 5y agoCALACalithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other lif
- 5y agoCALACalithera Biosciences to Participate in Two Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of ca
- 5y agoCALACalithera Biosciences Reports Second Quarter 2021 Financial Results and Recent HighlightsGlobeNewswire-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021-- SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Bioscien
- 5y agoCALACalithera Biosciences, inc (CALA) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsCALA earnings call for the period ending June 30, 2021.
- 5y agoCALACalithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of can
- 5y agoCALAFinal Data from Calithera Biosciences' Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life
- 5y agoCALACalithera to Present at the Jefferies 2021 Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-
- 5y agoCALAAntengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)PR NewswireSHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-cla
- 5y agoCALACalithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708GlobeNewswire--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera SOUTH SAN FRANCISCO, Calif. and SHAN
- 5y agoCALACalithera Biosciences Reports First Quarter 2021 Financial Results and Recent HighlightsGlobeNewswire--$102.9 Million in Cash and Investments at March 31, 2021-- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021-- SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA),
- 5y agoCALACalithera Biosciences, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / Calithera Biosciences, Inc. (NASDAQ:CALA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 5:00 PM Eastern Time. To listen to the event live or acc